Lynk Pharmaceuticals

Focus: Lynk Pharmaceuticals is a China-based kinase inhibitor specialist focused on immunoinflammatory and oncology indications. The company operates as a clinical-stage biotech with a multi-indication pipeline centered on LNK01001.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Lynk Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Lynk Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LNK01004 ointment 0.3%

Atopic Dermatitis

Phase 1

Clinical Trials (1)

NCT06553287Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

Phase 1

Help build intelligence for Lynk Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with 9 active trials across multiple therapeutic areas—LNK01001 has Phase 3 programs in three indications (RA, AS, AD), suggesting multi-label upside potential
Kinase inhibitor platform allows deep technical specialization in a proven mechanism class with broad application potential
China-based biotech at clinical inflection point, offering ground-floor opportunity for candidates joining ahead of major regulatory catalysts

Watch Out For

Zero active job postings and no disclosed headcount suggest either operational constraints or minimal hiring expansion planned
Limited public transparency on financials, funding status, and company stage creates uncertainty about runway and financial stability
Early-stage pipeline (only 3 Phase 3 programs, 4 Phase 2, 2 Phase 1) with no approved products means no near-term revenue cushion or market validation

Generated by Claude from Lynk Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LNK01002

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT04896112A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Phase 1

LNK01001

Ankylosing Spondylitis

Phase 2

Clinical Trials (1)

NCT06085534A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis

Phase 2